Document:

<PAGE>   1
                                                                   EXHIBIT 10.15

                         PROCESS DEVELOPMENT CONSORTIUM

                              MEMBERSHIP AGREEMENT

     This Agreement is entered into as of February 25, 1999 (the "Effective
Date") by and between Argonaut Technologies, Inc., a Delaware corporation with
its principal place of business at 887 Industrial Road, Suite G, San Carlos,
California 94070 ("Argonaut"), and Rohm and Haas Company, a ________________
corporation with its principal place of business at 727 Norristown Road, P.O.
Box 904, Spring House, PA 19477-1629 ("Member").

     WHEREAS, Argonaut has expertise in the development of instrumentation
utilizing automated organic chemistry for the preparation of small organic
molecules of broad chemical diversity;

     WHEREAS, Argonaut has established a Process Development Consortium ("PDC")
to consist of up to ten (10) members which are from the pharmaceutical,
biotechnology, and chemical industries, and Argonaut, for the purpose of
discussing and identifying desirable features, concepts and designs for
instrumentation for automating process development.

     WHEREAS, the Member wishes to be a member of the PDC, on the terms and
conditions herein.

     NOW THEREFORE, the parties agree as follows:

                               CONCEPT VALIDATION

     Every company who participates in individual meetings regarding the
Process Development Consortium has a high level of interest in the concept and
product. The product to be developed is code named "Process". There was
approval of the overall concept and validation of the primary specifications
and features.

                                 SPECIFICATIONS

     The general specifications for the Process Instrument are listed in Exhibit
A.

                               EXPECTED TIME LINE

     The current expected time line is outlined in Exhibit B.

                             MEMBERSHIP ADVANTAGES

     Member companies will benefit from early exposure to and hands on
experience with prototype instruments, interaction with peers from other
companies and most importantly, input into the design and development process
to ensure the development and commercialization of system for process chemistry
research and development needs.

                                       1
<PAGE>   2
                              TERMS OF MEMBERSHIP

     Term. The term of the Agreement is from the effective date of this
Agreement to the commercial release date of the Process Instrument.

     Participation. There will be a minimum of seven (7) and a maximum of ten
(10) members in the Consortium.

     Meetings. The Consortium will meet quarterly during the Term at Argonaut's
facilities in San Carlos, California, or another mutually agreed site. In
addition, Argonaut may meet with Member individually, as agreed by Argonaut and
such Member. Each party shall pay its own costs incurred in connection with
such meetings. Argonaut will be responsible for managing the Consortium,
including conducting the quarterly meetings, setting agendas and providing the
format for the discussion and exchange of ideas. Argonaut will bear the cost of
the meeting facilities.

     Prototypes. Members will have an opportunity to use the prototype
instruments and software at Argonaut's San Carlos, CA facility on a scheduled
basis during the Term of this Agreement.

     Fee. In consideration for its participation in the PDC, Member shall pay to
Argonaut, One Hundred and Five Thousand U.S. Dollars ($105,000). The payment is
due and payable within 30 days after execution of this agreement.

     Quest 205 Instrument. Upon signing this Agreement, Argonaut shall ship to
Member one (1) unit of Quest 205 (part number 900144). The title to the Quest
205 Instrument shall pass to the Member FOB Shipping Point. The Member will be
responsible for all applicable taxes, duties, VAT and freight charges.

     Process Instrument. Argonaut shall ship to Member one (1) unit of the
commercial Process Instrument according the Exhibit B. The title to the Process
Instrument shall pass to the Member FOB Shipping Point. The Member will be
responsible for all applicable taxes, duties, VAT and freight charges.

     Failure to Complete Consortium. If Argonaut fails to have at least seven
(7) members join the Consortium by March 31, 1999, Argonaut shall, by April 30,
1999, refund to Member all amounts paid less the price of the Quest 205
Instrument [*].

     Priority. In consideration for its participation in the PDC, and provided
that Member timely pays Argonaut the amounts set forth above, Member will be
entitled to priority status and discount with regard to the purchase of
subsequent commercial "Process" Instruments, not including the original Process
Instrument delivered under this Agreement. To implement priority status and take
advantage of the related discount, a purchase order must be received by June 30,
1999 to receive a [*] discount from the commercial, non-academic regional list
price established by Argonaut (the "List Price"). To implement priority status
and take advantage of the related discount, a purchase order must be received by
September 30, 1999 to receive a [*] discount from the commercial, non-academic
regional list price established by Argonaut (the "List Price"). Shipment
priority among Member and other PDC members will be based on the order of
receipt of purchase orders from Member or such other PDC members.

[*] Confidential Treatment Requested

                                       2

<PAGE>   3
      Confidential Information. In connection with the performance of this
Agreement, Argonaut or Member may not disclose confidential or proprietary
technical or business information to the other. There shall be no
Confidentiality Agreement in force under this Agreement, except for the
financial terms of this Agreement.

      Publicity. In connection with the performance of this Agreement, Argonaut
may use Member names in press release's announcing the formation of the
Consortium and Process Instrument related items.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their duly authorized officers.

ROHM AND HAAS COMPANY               ARGONAUT TECHNOLOGIES, INC.

BY: James S. Clovis                 BY: Mark W. Schwartz, Ph.D.
   ----------------------------

TITLE: Research Director            TITLE: Vice President,
      -------------------------            Marketing and Business Development

SIGNATURE: /s/ JAMES S. CLOVIS      SIGNATURE: /s/ Mark W. Schwartz
          ---------------------               -------------------------------

                                       3
<PAGE>   4
                                   EXHIBIT A

                                      [*]

[*] Confidential Treatment Requested

                                       4
<PAGE>   5
[*]

[*] Confidential Treatment Requested

                                       5
<PAGE>   6
                                   APPENDIX B

                             ARGONAUT TECHNOLOGIES
                         Process Synthesizer Instrument
                              Consortium Timelines

     The timeline detailed below is the current timeline Argonaut believes is
appropriate for the development of the Process Synthesizer. This timeline is
subject to changes based on input from Consortium members, changes to technical,
instrument or software specifications, or unforeseen technical problems. This
timeline should be taken as an indication of the current expectation and current
goals of the Process Development effort, but by no means the unequivocal
timeline for the development of the product.

   1. Consortium Membership Completed: .......................... March 1999

   2. First Consortium Meeting: ................................. March 1999
          Features and Specification Review and Justification
          Software Discussion
          Validation Experiments

  3. First Generation Prototype Operational: .................... February 1999

  4. Chemistry Performed: ....................................... February 1999

  5. Second Consortium Meeting: ................................. May 1999
          Review Prototype
          Review Chemistry
          Prototype Software Design Review
          Prototype Hardware Design Review

  6. Prototype Software Distribution: ........................... July 1999

  7. Advanced Prototype Instrument Operational: ................. August 1999

  8. Prototype Chemistry: ....................................... September 1999

  9. Third Consortium Meeting: .................................. September 1999

 10. Manufactured Pre-production Units Assembled: ............... October 1999

 11. Chemistry Validation: ...................................... October 1999

 12. First Commercial Unit Shipments to Consortium Members: ..... December 1999

                                       6<PAGE>   1
                                                                   EXHIBIT 10.16

                        RESEARCH COLLABORATION AGREEMENT

                                    BETWEEN

                             ARGONAUT TECHNOLOGIES

                                      AND

                           UNIVERSITY COLLEGE LONDON

                                       1
<PAGE>   2
THIS AGREEMENT is made the 1st day of September 1999

BETWEEN:

ARGONAUT TECHNOLOGIES of 887 Industrial Road, Suite G, San Carlos, California
94070, USA

and

UNIVERSITY COLLEGE LONDON of Gower Street, London, WC1E 6BT, UK

BACKGROUND:

A)    Argonaut Technologies ("Argonaut") is a company specialising in the
      development of equipment and chemical processes in the field of parallel
      organic synthesis.

B)    The Wolfson Institute for Biomedical Research ("WIBR") is an Institute of
      University College London ("UCL") with expertise in the validation of
      potential drug targets and the development of lead molecules based
      thereon.

C)    Trident(TM) is an automated chemical library synthesis system developed
      and marketed by Argonaut.

D)    Argonaut and WIBR now wish to enter into a research collaboration whereby
      Argonaut places a Trident machine at WIBR laboratories and WIBR will
      perform method development and use the machine for its own and
      collaborative research projects in accordance with the following terms and
      conditions:

NOW IT IS HEREBY AGREED as follows:

1.    CONDITIONS AND INTERPRETATION

1.1   In this Agreement the following words and phrases shall have the following
      meanings, unless the context requires otherwise:

      "Affiliate"       means any person, organisation or entity, which is
                        directly or indirectly controlled by, controlling or
                        under common control with any Party. The term "control"
                        (including, with correlative meaning, the terms
                        "controlled by" and "under common control with") as used
                        with respect to any person

                                       2
<PAGE>   3
                              or entity means the possession, directly or
                              indirectly, of the power to direct, or cause the
                              direction of, the management and policies of such
                              a person, organisation or entity, the ownership of
                              voting securities, or by contract, court order,
                              Statutory Instrument or otherwise. The ownership
                              of voting securities of a person, organisation or
                              entity, shall not, in itself, constitute "control"
                              for the purposes of this definition unless said
                              ownership is of a majority of the outstanding
                              securities entitled to vote of such a person,
                              organisation or entity.

"Agreement"                   means this agreement, as may be varied or
                              supplemented from time to time in accordance with
                              the provisions of this agreement.

"Commencement Date"           shall mean the date of the last signature below.

"Dedicated Employee"          the UCL employee funded by Argonaut under the
                              terms of this Agreement.

"Demonstration Visit"         shall mean occasions whereby a potential or
                              existing Argonaut client is brought to WIBR for
                              the purposes of discussing the Trident.

"Force Majeure"               means act of god, war, riot, civil commotion,
                              malicious damage, explosion, fire, flood, strike,
                              lock-out, shortage of materials or labour,
                              accident, breakdown of plant or machinery,
                              compliance with any law or governmental order,
                              rule, regulation or direction, or any other cause
                              beyond a Party's reasonable control.

"Method Development"          means any work specifically requested by Argonaut
                              to be carried out at WIBR to develop and/or
                              validate chemical processes. An Operating Plan
                              detailing the work to be undertaken, costs and
                              timescales will be agreed between the Parties
                              prior to commencing such Method Development.

"Party" or "Parties"          means Argonaut and/or UCL.

"Primary Demonstration        means where potential Argonaut client is brought
Visit"                        to WIBR to see the Trident in operation and
                              discuss its application with the Dedicated
                              Employee. Such a visit does not involve the
                              demonstration of client specified chemistry.

                                       3

<PAGE>   4
"Secondary Demonstration Visit"    means where a potential Argonaut client is
                                   brought to WIBR to have client specified
                                   chemistry demonstrated on the Trident.

1.2  In this Agreement:

     1.2.1  unless the context otherwise requires, all references to a
            particular Clause shall be a reference to that clause in this
            Agreement, as may be amended from time to time pursuant to the terms
            hereof;

     1.2.2  the headings are inserted for convenience only and shall be ignored
            when construing this Agreement;

     1.2.3  unless the contrary intention appears, words importing the masculine
            gender shall include the feminine and vice versa and words in the
            singular include the plural and vice versa and words importing the
            whole shall be treated as including a reference to any part thereof;

     1.2.4  unless the contrary intention appears, words denoting persons shall
            include any individual, partnership, company, corporation, joint
            venture, trust, association, organisation or other entity, in each
            case whether or not having separate legal personality;

     1.2.5  reference to the words "include" or "including" are to be construed
            without limitation to the generality of the preceding words; and

     1.2.6  reference to any statute, statutory instrument or regulation
            includes any modification or re-enactment of that statute, statutory
            instrument or regulation.

2.   FUNDING

2.1  Argonaut will upon a date to be agreed between the Parties following the
     execution of this Agreement, arrange for delivery of one Trident to WIBR.
     Argonaut will be responsible for the costs of delivery and installation of
     the Trident;

2.2  Argonaut will pay for the cost of one full-time person, the "Dedicated
     Employee", employed at WIBR to operate the Trident and agree to pay an
     overhead charge on this UCL salary of one hundred and twenty percent (120%)
     as set out in Annex 1;

                                       4
<PAGE>   5
2.3  Argonaut will in addition provide and pay for any training required by the
     Dedicated Employee in respect of operation and routine maintenance of the
     Trident;

2.4  Argonaut will reimburse UCL in full for the initial set-up costs of the
     Dedicated Employee up to a maximum of L10,000 (ten thousand pounds
     sterling), with items over L500 (five hundred pounds sterling) itemised;

2.5  Argonaut will reimburse UCL in full for consumables used either during the
     setting up and testing of the Trident at WIBR or during any subsequent
     Method Development undertaken by WIBR in the course of this collaboration
     such costs not to exceed L16,000 per annum. UCL shall include in its
     quarterly invoice the pro rata amount of the L16,000 per annum consumable
     budget agreed as set out in Annex 1. On each anniversary of this Agreement,
     an audit of the actual consumable expenses incurred by UCL will be
     undertaken and any amount not spent of the annual budget will be deducted
     from the final quarter's invoice;

2.6  Argonaut will, at all times retain ownership of the Trident, subject to
     Clause 9.3, and will assume responsibility for the servicing and repair of
     the Trident throughout the term of this collaboration;

2.7  Where Demonstration Visits are arranged, subject to Clause 3 of this
     Agreement, Argonaut will fully reimburse UCL for any expenses incurred as a
     result of demonstrating the Trident or entertaining the visiting client;
     and

2.8  UCL will issue Argonaut with an invoice covering the payments due to UCL on
     a quarterly in arrears basis. Payments to UCL will be due no late than
     thirty (30) days from the date of the invoice.

3.   DEMONSTRATION VISITS

3.1  From time to time Argonaut, or an affiliate, may request that it is able to
     use the Trident situated at WIBR for the purposes of demonstrating the
     device to prospective Argonaut clients. Such visits shall be scheduled to
     occur between 09.00hrs and 1700hrs and UCL shall not unreasonably refuse
     such a request provided that:

     3.1.1  in the case of Primary Demonstration Visits, Argonaut shall give at
            least one (1) week's prior notice to WIBR staff, the visit shall not
            occupy more than 30 (thirty) minutes of the Dedicated Employee's
            time and there shall be no more than eight (8) such visits in any
            calendar month;

     3.1.2  in the case of Secondary Demonstration Visits, Argonaut shall give
            at least two (2) weeks' prior notice to WIBR staff, the visit shall
            not occupy more

                                       5
<PAGE>   6
                than one half of a working day on the machine or for the
                Dedicated Employee and there shall be no more than two (2) such
                visits during any calendar month; and

        3.1.3   Secondary Demonstration Visits, shall not be arranged when the
                Dedicated Employee plans to be absent from work. In the case of
                an unplanned absence, WIBR retains the right to cancel such a
                Demonstration Visit without liability.

4.   OWNERSHIP OF INTELLECTUAL PROPERTY

4.1  All intellectual property, whether patentable or not, that arises out of
     Method Development funded by Argonaut shall be the exclusive property of
     Argonaut and Argonaut grants UCL a royalty-free non-exclusive license to
     use such intellectual property.

     4.1.1  UCL shall notify at Argonaut as soon as practicable of any such
            intellectual property that arises whilst performing Method
            Development; and

     4.1.2  UCL shall, at Argonaut's expense, execute such documents. Powers
            of Attorney, grants of authority, assignments and licenses as
            Argonaut may request to give full force and effect to the provisions
            of this Clause and to enable Argonaut to record its interests in
            such property at the appropriate registries (worldwide).

     4.1.3  Should Argonaut elect not to seek protection of any such
            intellectual property but where UCL believes protection would be
            beneficial for UCL's business, UCL may, at its own expense and with
            the prior written approval of Argonaut, seek protection of any such
            intellectual property. Argonaut shall, at UCL's expense, execute
            all such documents, Powers of Attorney, grants of authority,
            assignments and licenses as Argonaut may request to give full force
            and effect to the provisions of this Clause and to enable UCL to
            record its interests in such property at the appropriate registries
            (worldwide).

     4.1.4  Where UCL proceeds to seek protection of intellectual property
            pursuant to Clause 4.1.3, UCL shall grant Argonaut a worldwide,
            royalty free license, without the right to sub-license, to use such
            technology for the purpose of conduction its own business.

4.2  All intellectual property arising from use of the Trident in WIBR's
     research programmes shall be the exclusive property of UCL, subject to the
     terms of any agreement governing sponsorship of that research programme.
     Argonaut waives

                                       6

<PAGE>   7
     all right and future claim to any such intellectual property under the
     terms of this Agreement.

4.   RESTRICTIONS

5.1  During the term of this Agreement, WIBR shall not to enter into any other
     research collaboration within the field of development of enabling
     technology for parallel organic synthesis without the prior written
     permission of Argonaut.

6.   CONFIDENTIALITY

6.1  Except as otherwise permitted hereunder, each Party undertakes and agrees
     not at any time for any reason whatsoever to disclose or permit to be
     disclosed to any third party or otherwise make use of or permit to be made
     use of, any trade secrets or confidential information relating to the other
     Party's technology or the business affairs or finances of the other Party
     or of any affiliates, suppliers, agents, distributors, or customers of the
     Party which come into its possession pursuant to this Agreement. Such
     information should be clearly marked as "Confidential" and, if disclosed
     orally, subsequently reduced to writing within thirty (30) days and marked
     "Confidential".

6.2  Each Party shall ensure that all of its agents, employees who have access
     to the information referred to in Clause 6.1 are:

     6.2.1  made aware that such information is secret and confidential; and

     6.2.2  bound by undertakings of confidentiality (whether in their contracts
            of employment or otherwise) not to make any disclosure or use of
            such information but to keep the same confidential.

6.3  The obligations of confidence set out in this Clause 6 shall not extend to
     any information which:

     6.3.1  is, or shall become, generally available to the public otherwise
            than by reason of a breach of the recipient Party of the provisions
            of this Clause 8; or

     6.3.2  is known to the recipient Party and is at its free disposal prior to
            its receipt from the other Party, as can be shown by written record;
            or

     6.3.3  is subsequently disclosed to the recipient Party without obligations
            of confidence by a third party owing no such obligations in respect
            thereof; or

                                       7

<PAGE>   8
        6.3.4   is required to be disclosed by any applicable law or any
                regulatory authority to which a Party is from time to time
                subject to; or

        6.3.5   is independently developed by a person or person with no access
                to the confidential information disclosed by a Party, as
                demonstrated by written records; or

        6.3.6   disclosed to a third party for whom you have had written
                permission from the discloser to pass the information to,
                subject to the third party undertaking obligations of
                confidence equivalent to those contained in this Agreement.

6.4     The obligations of each Party under this Clause 6 shall survive the
        expiration or termination of this Agreement for ten (10) years from the
        date of expiry or termination, as the case may be.

7.      PUBLICATION

7.1     Where UCL wishes to publish the results of Method Development performed
        UCL will be free to do so provided that:

        7.1.1   UCL have informed Argonaut in writing of the results to be
                disclosed not less than thirty (30) days prior to disclosure in
                order for Argonaut to evaluate whether any patent protection
                should be sought. Argonaut must inform UCL in writing within
                that thirty (30) day period if it wishes to seek such
                protection. In the absence of written notification UCL shall be
                free to publish;

        7.1.2   If Argonaut, at its sole discretion, decides patent protection
                is to be applied for, there shall be a further delay not to
                exceed forty-five (45) days during which Argonaut, at its own
                expense, may file appropriate patent application(s).

        7.1.3   Where the Trident has been successfully utilised in a WIBR
                research programme, Argonaut may, with the prior written
                permission of UCL, disclose statements relating to the generic
                use of the Trident in drug discovery for the purposes of
                marketing and promoting the Trident.

7.2     On all published articles referring to results involving the use of the
        Trident UCL agrees to acknowledge the use of the Trident in the research
        programme and the collaborative support of Argonaut.

                                       8
<PAGE>   9
8.   TERM AND TERMINATION

8.1  This Agreement will commence on the first day of September 1999 and remain
     in force for two (2) years from the Commencement Date unless terminated
     pursuant to Clause 8, or extended pursuant to Clause 13.

8.2  Either Party (the "Terminating Party") shall have the right to terminate
     this Agreement forthwith upon giving written notice of termination to the
     other Party (the "Defaulting Party") upon the occurrence of any of the
     following events at any time during this Agreement:

     8.2.1     the Defaulting Party commits a material breach of this Agreement
               which in the case of a breach capable of remedy shall not have
               been remedied within sixty (60) days of the receipt by it of a
               notice identifying the breach and requiring its remedy;

     8.2.2     the Defaulting Party for a period of longer than sixty (60) days
               suspends payment of its debts or otherwise ceases or threatens to
               cease to carry on its business or becomes bankrupt or insolvent
               (including without limitation being deemed to be unable to pay
               its debts);

     8.2.3     a proposal is made or a nominee or supervisor is appointed for a
               composition in satisfaction of the debts of the Defaulting Party
               or a scheme or arrangement of its affairs, or the Defaulting
               Party enters into any composition or arrangement for the benefit
               of its creditors, or proceedings are commenced in relation to the
               Defaulting Party under any law, regulation or procedure relating
               to the re-construction or re-adjustment of debts (including where
               a petition is filed or proceeding commenced seeking any
               reorganisation, arrangement, composition, or re-adjustment under
               any applicable bankruptcy, insolvency, moratorium, reorganisation
               or other similar law affecting creditors rights or where the
               Defaulting Party consents to, or acquiesces in, the filing of
               such a petition);

     8.2.4     the Defaulting Party takes, without the consent of the
               Terminating Party (such consent not be unreasonably withheld),
               any action, or legal proceedings are started or other steps taken
               by a third party, with a view to:

               (a)  the winding up or dissolution of the Defaulting Party (other
                    than for the reconstruction of a solvent company for any
                    purpose, including the inclusion of any part of the share
                    capital of the Defaulting Party in any official stock
                    exchange listing or an application by the Defaulting Party
                    for registration as a public

                                       9

<PAGE>   10
               company in accordance with the requirements of the Companies
               Act 1985); or

          (b)  the appointment of a liquidator, trustee, receiver,
               administrative receiver, receiver manager, interim receiver
               custodian, sequestrator or similar officer of the Defaulting
               Party against the Defaulting Party or a substantial part of the
               assets of the Defaulting Party, or anything analogous to any of
               the foregoing occurs under the laws of any country.

     8.3  Upon termination or expiry of this Agreement, UCL will have the
          option to purchase the Trident at a depreciated value, such
          depreciation deemed to be a linear depreciation over a four (4) year
          period commencing on the date of delivery of the Trident to WIBR in
          the Cruciform Building, thereafter the value of the Trident being
          written off.

     8.4  Upon termination or expiry of this Agreement, Argonaut will pay to
          UCL, within sixty (60) days, all sums owing which have accrued prior
          to the date of termination.

     8.5  Termination or expiry of this Agreement for whatever reason shall not
          affect the accrued rights of the Paries arising in any way out of
          this Agreement as at the date of termination and in particular the
          right to recover damages and interest, and the provisions of Clauses
          4, 6, 8, 11, 14 and 16 shall survive this Agreement and shall remain
          in full force and effect.

     9.   FORCE MAJEURE

     9.1  If UCL is unable to carry out any of its obligations under this
          Agreement due to Force Majeure this Agreement shall remain in effect
          but UCL's obligations under this Agreement and the obligations of
          Argonaut under this Agreement shall be suspended for a period equal
          to the duration of the circumstance of Force Majeure provided that:

          9.1.1     the suspension of UCL's performance is of not greater scope
                    or duration than is required by Force Majeure:

          9.1.2     UCL gives Argonaut as soon as practicable notice describing
                    the circumstance of the Force Majeure, including the nature
                    of the occurrence and its expected duration, and continues
                    to furnish regular reports to Argonaut during the period of
                    the Force Majeure;

          9.1.3     UCL uses all reasonable efforts to remedy its inability to
                    perform and to mitigate the effects of the circumstances of
                    Force Majeure; and

                                       10
<PAGE>   11
        9.1.4   as soon as practicable after the event which constitutes Force
                Majeure the Parties shall discuss how best to progress the
                collaboration between them, as far as possible in accordance
                with this Agreement.

9.2     If Force Majeure continues for more than three (3) months from the
        first occurrence of the Force Majeure, either Party may give sixty (60)
        days written notice to the other Party to terminate this Agreement and
        termination shall occur if Force Majeure is still continuing at the end
        of that sixty (60) day notice period.

10.     GOVERNING LAW AND JURISDICTION

10.1    The validity, construction and performance of this Agreement shall be
        governed by the laws of England and be subject to the exclusive
        jurisdiction of the English courts.

11.     WAIVER

11.1    Neither Party shall be deemed to have waived any of its rights or
        remedies whatsoever unless the waiver is made in writing and signed by
        a duly authorised representative of that Party. In particular, no delay
        or failure of a Party in exercising or enforcing any of its rights or
        remedies whatsoever shall operate as a waiver of those rights or
        remedies so as to preclude or impair the exercise or enforcement of
        those rights or remedies nor shall any partial exercise or enforcement
        of that right or remedy by that Party.

12.     SEVERANCE OF TERMS

12.1    If the whole or any part of this Agreement is or becomes or is declared
        illegal, invalid or unenforceable in any jurisdiction for any reason
        (including both by reason of the provisions of any legislation and also
        by reason of any court which either has jurisdiction over this
        Agreement or has jurisdiction over any of the Parties):

        12.1.1  In the case of illegality, invalidity or un-enforceability of
                the whole of this Agreement it shall terminate only in
                relation to the jurisdiction in question; or

        12.1.2  in the case of the illegality, invalidity or un-enforceability
                of part of this Agreement that part shall be severed from this
                Agreement in the jurisdiction in question and that illegality,
                invalidity or un-enforceability

                                       11
<PAGE>   12
          shall not in any way whatsoever prejudice or affect the remaining
          parts of this Agreement which shall continue in full force and effect.

12.2 If in the reasonable opinion of either Party any severance under this
     Clause 12 materially affects the commercial basis of this Agreement, the
     Parties shall discuss, in good faith, ways to eliminate the material
     effect.

13.  ENTIRE AGREEMENT AND VARIATIONS

13.1 This Agreement embodies and sets forth the entire agreement and
     understanding of the Parties and supersedes all prior oral or written
     agreements, understandings or arrangements relating to the specific
     subject matter of this Agreement. Neither Party shall be entitled to rely
     on any agreement, understanding or arrangement, which is not expressly set
     forth in this Agreement.

13.2 No director, officer, employee or agent of either Party is authorised to
     make any representation or warranty to the other Party not contained in
     this Agreement, and each party acknowledges that it has not relied on any
     such oral or written representation or warranties.

13.3 No variation, amendment, modification or supplement to this Agreement shall
     be valid unless made in writing in the English language and signed by a
     duly authorised representative of each Party.

14.  NOTICES

14.1 Any notice or other document to be given under this Agreement shall be in
     writing in the English language and shall be deemed to have been duly given
     if sent by fax, recorded mail or registered mail to a Party at the fax
     number or address set out below for such Party or such other address as the
     Party may from time to time designate by written notice to the other Party.

     Address of Argonaut

     Argonaut Technologies
     887 Industrial Road
     Suite G
     San Carlos
     California 94070
     USA

     For the attention of the David Binkley Ph.D
     Fax No. +1 650 598 1359

                                       12

<PAGE>   13
      Address of WIBR

      Wolfson Institute for Biomedical Research
      University College London
      Gower Street
      London
      WC1E 6BT
      UK

      For the attention of Professor Ken Powell
      Fax No. +44 (0) 171 209 0470

      Any notices sent to WIBR shall be copied to UCLi, 2-16 Torrington Place,
      London, WC1E 7HN, UK (Fax No. 0171 209 0681) and marked for the attention
      of Mr I Chater.

14.2  Any notice given pursuant to this Clause 15 shall be deemed to have been
      received:

      14.2.1 in the case of sending by post, on the day five (5) days after the
      day of posting; or

      14.2.2 in the case of sending by fax at the time the sender's fax machine
      receives a clear transmission report.

15.   COSTS

15.1  Each Party shall bear its own legal costs, legal fees and other expenses
      incurred in the preparation and execution of this Agreement.

16.   PUBLIC STATEMENTS

16.1  Except as provided in Clause 16.2, neither Party shall, without the prior
      written consent of the other Party:

      16.1.1 use in advertising, publicly or otherwise, any trade name, personal
      name, trademark, trade device, symbol, or any abbreviation, contraction or
      simulation thereof, owned by that representing Party; or

      16.1.2 represent, either directly or indirectly, that any product or
      service of the other Party is a product or service of the representing
      Party or that it is

                                       13
<PAGE>   14
               made in accordance with or utilises the information or documents
               of the other Party.

16.2  The restrictions in Clause 16.1 shall not apply to the following:

      16.2.1 a press release, in a form agreed to by the Parties, publicly
             announcing this Agreement; or

      16.2.2 use as required by any applicable law or governmental regulation.

17.   PARTNERSHIP

17.1  Nothing in this Agreement shall be construed as creating a partnership or
      joint venture between the Parties or constituting one Party as the agent
      of the other Party for any purpose whatsoever and neither Party shall have
      the authority or power to bind the other Party or to contract in the name
      of or create a liability against the other Party in any way or for any
      purpose.

18.   FURTHER ASSURANCE

18.1  Each Party shall do and execute or procure to be done and executed all
      necessary acts, deeds, documents and things that give full effect to this
      Agreement. Except as otherwise provided herein, the cost and expense of
      doing so shall be borne by the Party who is required to take such action.

IN WITNESS whereof this Agreement has been signed by duly authorised officers of
the Parties:

                                       14
<PAGE>   15
Signed by: /s/ DAVID P. BINKLEY
           --------------------------
           For and on behalf of
           ARGONAUT TECHNOLOGIES INC.

Name:      David P. Binkley

Title:     President and CEO

Date:      September 1, 1999

Signed by: /s/ DRUSILLA KENNEY
           --------------------------
           For and on behalf of
           UNIVERSITY COLLEGE LONDON

Name:      Drusilla Kenney

Title:     Contracts Manager, UCL

Date:      2 October 1999

Acknowledged by: /s/ KEN POWELL
                 --------------------
                 For and on behalf of
                 WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH

Name:            Ken Powell

Title:           Deputy Director

Date:            12/10/99

Wolfson-Argonaut
09/02/99                               15
<PAGE>   16
                                    ANNEX 1

    RESEARCH PROJECT COSTINGS FOR 2 YEARS: (ALL FIGURES ARE POUNDS STERLING)

DEDICATED EMPLOYEE: (RA1A spine point 4-5)

<TABLE>
<CAPTION>
                                      Year 1             Year 2
                                      ------             ------
<S>                                   <C>      <C>       <C>
Basic Salary                          15,735              16,655

London Weighting                       2,134               2,134

N.I.                                   1,351               1,415

SA                                     2,502               2,630

Total                                 21,722              22,834

Prov. for pay award                    1,086               2,340

Total                                 22,808              25,174

Consumables                           16,000              16,000

Set-up Equipment                      10,000

Overheads (120%)                      27,370              30,209

TOTAL                                 76,178              71,384
----------------------------------------------------------------
GRAND TOTAL                                    147,562
----------------------------------------------------------------
</TABLE>

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]